To evaluate the efficacy and safety of Longxiang Pingchuan capsule in the treatment of bronchial asthma with chronic duration (phlegm and stasis blocking lung syndrome)

Phase 4

• Conditions: Bronchial asthma

• Registration Number: ITMCTR2200006867
• Lead Sponsor: Dongzhimen Hospital Beijing University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

126/5000
(1) Consistent with the diagnosis of bronchial asthma, in chronic duration, the severity of mild to moderate;

(2) The level of asthma control in the past month was partially controlled;

(3) In line with the syndrome differentiation of phlegm and blood stasis;

(4) Aged 18-79 (including 18 and 79), both sexes;

(5) Voluntarily participate in the clinical trial with informed consent and signed informed consent.

Exclusion Criteria

(1) Severe asthma; Atypical asthma, such as cough variant asthma, chest tightness variant asthma, occult asthma; Merger of upper and lower respiratory tract infection, atelectasis, pneumonia, pulmonary tuberculosis, pulmonary fibrosis, thoracic deformity, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, allergic bronchial lung music bacterium disease, allergic granulomatous vasculitis special types, such as infection, restrictive pulmonary disease and other air obstructive pulmonary disease;

(2) Accompanied by gastrointestinal discomfort symptoms such as diarrhea, epigastric discomfort or noise;

(3) Complicated with serious diseases of major organs or systems such as heart, brain, liver, kidney, respiratory system and blood system;

(4) Liver function ALT and AST exceeded the upper limit of the normal reference value 1.5 times or Scr exceeded the upper limit of the normal reference value;

(5) Allergic to test drugs (including positive drugs) or their ingredients and excipients;

(6) Pregnant or lactating women, planning to become pregnant, patients of childbearing age who are unable or unwilling to take adequate contraceptive measures during the trial period or their spouses are unwilling to take contraceptive measures;

(7) Suspected or confirmed history of alcohol dependence, drug abuse or drug use;

(8) having intellectual or mental disorders;

(9) Participating in or currently participating in clinical trials of other drugs or medical devices within 3 months;

(10) The investigator did not consider it appropriate to participate in the clinical trial.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Good asthma control rate;

Secondary Outcome Measures

Name	Time	Method
AQLQ;ACT;Number of acute asthma attacks;Grade of asthma control level;FEV1\FVC\FEV1/FVC\PEF\MMEF;